Glaucoma Trial, Recruiting NCT05039684 Sponsor: Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT05039684
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with primary open-angle glaucoma or high eye pressure (ocular hypertension), as defined by the Early Manifest Glaucoma Trial criteria
  • People aged 18 or older
  • People who have signed a consent form agreeing to take part
  • People who have been using one of these specific eye drop medications for 3 months or more: tafluprost 0.0015%, latanoprost 0.005% with BAK 0.2mg/ml, or latanoprost 0.005%
  • People with high eye pressure who have never received any treatment for this condition (if in the untreated group)
  • People who have no other eye diseases, and no history of other eye diseases that began before they started using eye pressure-lowering medication

Who may not be able to join:

  • People who have had eye surgery in the last 6 months
  • People who have had an active eye surface disease (unrelated to glaucoma or high eye pressure) within the last 6 months
  • People who have used any eye drops other than those being studied in the last 3 months
  • People who use preserved artificial tears (preservative-free artificial tears used no more than 4 times per day may be permitted, but must be stopped 5 days before joining the trial — confirm with trial site)
  • People who have worn contact lenses in the last 4 weeks
  • People with a mental or physical condition that would prevent them from completing the tests required by the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 983184734

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Registry
ClinicalTrials.gov
Start date
1 October 2021
Est. completion
1 December 2025

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Inflammatory response in ocular surface secondary to prostaglandin use; Conjunctival cell phenotype and inflammatory infiltration; Changes in oxidative stress in the tear film

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov